PDS Biotechnology (PDSB) Projected to Post Quarterly Earnings on Wednesday

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) will likely be issuing its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. Parties may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 8:00 AM ET.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last announced its quarterly earnings results on Monday, March 30th. The company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.06. On average, analysts expect PDS Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

PDS Biotechnology Stock Performance

Shares of PDSB stock opened at $1.06 on Wednesday. The stock has a fifty day moving average of $0.82 and a 200 day moving average of $0.85. PDS Biotechnology has a 52 week low of $0.51 and a 52 week high of $1.92. The firm has a market capitalization of $57.66 million, a price-to-earnings ratio of -1.41 and a beta of 1.51. The company has a quick ratio of 2.98, a current ratio of 2.98 and a debt-to-equity ratio of 1.27.

Wall Street Analyst Weigh In

PDSB has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of PDS Biotechnology in a research note on Tuesday, April 21st. Wall Street Zen raised PDS Biotechnology from a "sell" rating to a "hold" rating in a research note on Saturday, April 4th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $15.00 price target on shares of PDS Biotechnology in a research note on Wednesday, April 15th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, PDS Biotechnology presently has an average rating of "Hold" and an average target price of $9.00.

Hedge Funds Weigh In On PDS Biotechnology

Several institutional investors and hedge funds have recently added to or reduced their stakes in PDSB. Armistice Capital LLC purchased a new position in PDS Biotechnology during the fourth quarter valued at $2,182,000. Squarepoint Ops LLC lifted its position in PDS Biotechnology by 116.1% during the third quarter. Squarepoint Ops LLC now owns 291,627 shares of the company's stock valued at $295,000 after buying an additional 156,662 shares during the period. Commonwealth Equity Services LLC lifted its position in PDS Biotechnology by 117.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company's stock valued at $151,000 after buying an additional 106,300 shares during the period. Susquehanna International Group LLP lifted its position in PDS Biotechnology by 603.7% during the third quarter. Susquehanna International Group LLP now owns 94,344 shares of the company's stock valued at $95,000 after buying an additional 80,937 shares during the period. Finally, Jane Street Group LLC purchased a new position in PDS Biotechnology during the second quarter valued at $92,000. Hedge funds and other institutional investors own 26.84% of the company's stock.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company's proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.